Prostate cancer (PCa) is the second most frequently diagnosed cancer among men. The use of IL-17A and its receptor IL-17RA as prognostic markers for PCa has shown promising results. We analyzed the clinical data of 77 patients with PCa after radical prostatectomy with lymphadenectomy and lymph node metastasis (LN+). We assessed the expression levels of IL-17A and IL-17RA in cancer cells in prostate and, for the first time, also in LN+. Prostate IL-17A expression positively correlated with BMI (p= 0.028). In LN+, the expression of IL-17A was positively correlated with the percentage of affected lymph nodes (p= 0.006) and EAU risk groups (p= 0.001). Additionally, in the group with high IL-17A expression in LN+, the extracapsular extension (ECE) of the prostate was significantly more frequent (p= 0.033). Also, significant correlations with the level of IL-17RA expression was found—expression was higher in prostate than in LN+ (p= 0.009); in LN+, expression positively correlated with the EAU risk group (p= 0.045), and in the group of high expression in LN+ ECE of lymph nodes was detected significantly more often (p= 0.009). Our findings support the potential role of IL-17A and IL-17RA as PCa markers; however, further studies are needed to determine their roles and potential clinical applications.
前列腺癌（PCa）是男性中第二常见的恶性肿瘤。将IL-17A及其受体IL-17RA作为前列腺癌预后标志物的研究已显示出良好前景。本研究分析了77例接受根治性前列腺切除及淋巴结清扫术后发生淋巴结转移（LN+）的前列腺癌患者的临床资料。我们评估了IL-17A和IL-17RA在前列腺癌细胞中的表达水平，并首次在淋巴结转移灶中进行同步检测。结果显示：前列腺组织中IL-17A表达水平与体重指数（BMI）呈正相关（p=0.028）；在淋巴结转移灶中，IL-17A表达与受累淋巴结比例（p=0.006）及欧洲泌尿外科学会（EAU）风险分级（p=0.001）呈正相关。此外，在淋巴结转移灶高表达IL-17A的患者组中，前列腺包膜外侵犯（ECE）发生率显著更高（p=0.033）。同时发现IL-17RA表达具有以下特征：前列腺原发灶表达水平显著高于淋巴结转移灶（p=0.009）；在淋巴结转移灶中，其表达与EAU风险分级呈正相关（p=0.045）；且在淋巴结转移灶高表达组中，淋巴结包膜外侵犯检出率显著更高（p=0.009）。本研究证实了IL-17A和IL-17RA作为前列腺癌标志物的潜在价值，但其具体作用机制及临床应用前景仍需进一步研究验证。
肿瘤(癌症)患者之家